The conditions for obtaining patient’s access to new medicinal products have changed dramatically during recent years along with expanding pressure on healthcare budgets. What used to be fairly uncomplicated marketing activities after regulatory approval, has transformed into a discipline requiring crucial negotiations between sponsors and payers based on technology assessments. To support such negotiations, focus is not only on clinical development programs to demonstrate efficacy and safety but also on health economic analysis based on real-world evidence of treatment outcome.
As a consequence, Market Access is now a separate discipline in many pharmaceutical companies. This meeting will provide a general introduction to the field, how are new pharmaceuticals appraised in public health care evaluations, what are the typical access barriers and how can these be addressed in clinical development and by means of real-world evidence?
14.30–15.10 How are new medicinal products appraised and how is this affecting market access?
Sophie Cooper, Scientific Adviser, Science Policy and Research programme at NICE (National Institute for Health and Care Excellence), UK
15.10–15.50 Strategies and tools in the industry to enable patient access
Tim Slee, Corporate Vice President, Global Patient Access, Novo Nordisk A/S), Denmark
15.50–16.10 Break with refreshments
16.10–16.30 Exercise: Negotiating market access for a fictional drug
Morten Jaeger and team, Workz A/S, Copenhagen, Denmark
16.30-16.45 Discussion and questions to the negotiation
Registration no later than March 1st at www.farmaceutisk-selskab.dk
No entry fee, non-members are also welcome to participate in the meeting.